17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Digoxin remains commonly used for rate control in atrial fibrillation, but limited data exist supporting this practice and some studies have shown an association with adverse outcomes. We examined the independent association between digoxin and risks of death and hospitalization in adults with incident atrial fibrillation and no heart failure.

          Related collections

          Author and article information

          Journal
          Circ Arrhythm Electrophysiol
          Circulation. Arrhythmia and electrophysiology
          1941-3084
          1941-3084
          Feb 2015
          : 8
          : 1
          Affiliations
          [1 ] From the Department of Medicine, Yale University School of Medicine, New Haven, CT (J.V.F.); Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena (K.R., T.N.H.); Departments of Medicine (M.F., A.S.G.) and Epidemiology and Biostatistics (A.S.G.), University of California, San Francisco; Division of Research, Kaiser Permanente Northern California, Oakland (N.U., N.K.P., A.S.G); Division of Cardiology, Kaiser Permanente Santa Clara Medical Center, CA (A.S.); Clinical Epidemiology Unit, Massachusetts General Hospital, Boston (L.H.B., D.E.S.); Harvard Medical School, Boston, MA (D.E.S.); and Department of Health Research and Policy, Stanford University School of Medicine, CA (A.S.G.).
          [2 ] From the Department of Medicine, Yale University School of Medicine, New Haven, CT (J.V.F.); Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena (K.R., T.N.H.); Departments of Medicine (M.F., A.S.G.) and Epidemiology and Biostatistics (A.S.G.), University of California, San Francisco; Division of Research, Kaiser Permanente Northern California, Oakland (N.U., N.K.P., A.S.G); Division of Cardiology, Kaiser Permanente Santa Clara Medical Center, CA (A.S.); Clinical Epidemiology Unit, Massachusetts General Hospital, Boston (L.H.B., D.E.S.); Harvard Medical School, Boston, MA (D.E.S.); and Department of Health Research and Policy, Stanford University School of Medicine, CA (A.S.G.). Alan.S.Go@kp.org.
          Article
          CIRCEP.114.002292 NIHMS645139
          10.1161/CIRCEP.114.002292
          25414270
          © 2014 American Heart Association, Inc.

          arrhythmia, atrial fibrillation, digoxin, morbidity, mortality

          Comments

          Comment on this article

          Similar content 857

          Cited by 17